Comparison · NCT02580240-c57eee4d
Hydrocortisone vs Placebo: All Cause Mortality
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Hydrocortisone vs Placebo: All Cause Mortality. Trial comparisons, record NCT02580240-c57eee4d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02580240-c57eee4d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.397 | 0.281 | 0.525 | wilson | |
| Risk in group 2 | 0.317 | 0.213 | 0.442 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0799 | -0.0909 | 0.245 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.25 | 0.768 | 2.04 | log | |
| Odds ratio, group 1 over group 2 | 1.42 | 0.665 | 3.02 | log | |
| Number needed to treat, for one more participant with the outcome on Hydrocortisone than on Placebo | 12.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Hydrocortisone | Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).~Hydrocortisone: Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped). | 23 | 58 | OG001 |
| Group 2 | Placebo | Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.~saline: Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar. | 19 | 60 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- All Cause Mortality
- Description
- Death from any cause at 90 days after the onset of septic shock
- Time frame
- 90 days
- Population
Source ClinicalTrials.gov
Trial
- Title
- Initiation of Hydrocortisone for the Treatment of Septic Shock
- NCT number
- NCT02580240
- Phases
- NA
- Conditions
- Septic Shock
- Interventions
- Hydrocortisone, saline
- Lead sponsor
- Northern Jiangsu People's Hospital
- Results first posted
- 2017-08-07
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02580240?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02580240-c57eee4d